Last year, the targeted drug for the rare disease spinal muscular atrophy (SMA) was turned from a price of 700,000 RMB (around $100,000) to an affordable national healthcare insured drug after the National Healthcare Security Administration's 2021 insured drug Medicare negotiations.
Starting January 1, 2022, SMA patients across the country were getting access to these "overpriced drugs".
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3